- $430.67m
- $372.45m
Forte Biosciences Inc: Falls after FY20 net loss widens
Brief: Forte Biosciences Inc Announces 4Q And Full Year 2020 Results
Brief: Forte Biosciences Reports Q3 Loss Per Share Of $0.45
Brief: Forte Biosciences Announces Pricing Of $40.0 Million Public Offering Of Common Stock
Brief: Forte Enters Into At Market Issuance Sales Agreement With Ladenburg Thalmann & Co
Brief: Forte Biosciences Announces Proposed Public Offering Of Common Stock
Brief: Forte Biosciences Announces The FDA Has Granted Fast Track Designation To FB-401 For The Treatment Of Atopic Dermatitis
U.S. STOCKS ON THE MOVE-Big banks, oil majors, airlines, Tesla Inc, Bloom Energy Corp
Brief: Forte Biosciences Inc Announces First Patient Dosed In The Clinical Trial Of FB-401 For The Treatment Of Children And Adults With Atopic Dermatitis
Brief: Forte Biosciences Announces Full Publication Of Phase 1/2 Data In Science Translational Medicine
Brief: Forte Biosciences Enters Into At Market Issuance Sales Agreement With Ladenburg Thalmann
Brief: Forte Biosciences Reports Inducement Grants Under Nasdaq Listing Rules
Brief: Forte Biosciences Posts Q2 Loss Per Share Of $9.52
Brief: Forte Biosciences Announces Issuance Of New U.S. Patent
Brief: Tocagen Says On April 28 Received Notice From Nasdaq - SEC Filing
Brief: Tocagen Quarterly Loss Per Share $0.43
Brief: Tocagen Q1 Loss Per Share $0.43
Brief: Tocagen Makes Prepayment Of $4.8 Mln Under Loan And Security Agreement With Oxford Finance, Silicon Valley Bank
Brief: Steven Oliveira Roth Ira Reports 11.4% Passive Stake In Tocagen